Follicular lymphoma is the second most common type of non-Hodgkin lymphoma, with approximately 15,000 cases in the US each year. Image credit: Shutterstock/Nemes Laszlo.
The approval is for the drug’s use in combination with Roche’s Gazyva (obinutuzumab). Adults with relapsed or refractory forms of the cancer who have tried two or more lines of systemic therapy will be eligible for the combination therapy.
The FDA go-ahead in follicular lymphoma marks the fifth approved indication – all of which are in B-cell malignancies – for the monoclonal antibody in the US. The blockbuster drug has already hit sales of $1.3bn in 2023, with it forecast to see sales of $4.2bn by 2029, according to GlobalData’s Pharma Intelligence Centre.
BeiGene’s Brukinsa is now the first BTK inhibitor approved for follicular lymphoma in the US and has the broadest label compared to competitors, BeiGene’s chief medical officer Mehrdad Mobasher said in a 7 March press release.
See Also:
FDA delays action on Lilly’s donanemab, intent on advisory committee meeting
The FDA based its decision on results from BeiGene’s Phase II ROSWOOD trial (NCT03332017). The trial, which enrolled 217 patients, compared Brukinsa plus Gazyva to Gazyva alone. The overall response rate (ORR) in the combo arm was 69%, higher than the 46% seen in those taking the monotherapy. The ORR in patients taking Brukinsa plus Gazyva was maintained after 18 months.
Whilst the combo therapy was generally well-tolerated, serious adverse reactions occurred in 35% of patients. This led to 17% of patients permanently discontinuing the therapy.
For full approval, BeiGene will likely need clinical benefit consolidation from its ongoing confirmatory MAHOGANY trial (NCT05100862).
Follicular lymphoma is the second most common type of non-Hodgkin lymphoma, with approximately 15,000 cases in the US each year. Whilst the disease is incurable, treatments can help patients live longer.
China-founded BeiGene will face competition in the third-line follicular lymphoma treatment market, in which big pharma features heavily.
Novartis’ CD-19-directed immunotherapy Kymriah gained accelerated approval from the FDA in May 2022. Kymriah, a CAR-T therapy, has demonstrated strong efficacy here – posting an ORR of 86%.
Roche is offering an off-the-shelf treatment in the form of its bispecific antibody Lunsumio (mosunetuzumab). Lunsumio was granted accelerated approval in January 2023.
The Follicular Lymphoma Foundation said that “the emergence of new treatment options, which have been shown to be effective and well-tolerated, including second-generation BTK inhibitorsBTK inhibitors such as zanubrutinib in combination with existing therapies, brings hope to those dealing with advanced follicular lymphoma”.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.